SCHEMBL2098313

SCHEMBL2098313

CCCCCCCCc1ccccc1NC(=O)OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 2/20 0.49
POLB P06746 1/20 0.49
LIPG Q9Y5X9 1/20 0.49
SLC16A3 O15427 4/20 0.48
THRA P10827 1/20 0.48
THRB P10828 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C19 P33261 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
BID P55957 3/20 0.46
MCL1 Q07820 3/20 0.46
BCL2L1 Q07817 2/20 0.46
BAK1 Q16611 2/20 0.46
KAT8 Q9H7Z6 2/20 0.46
PPARG P37231 1/20 0.46
EP300 Q09472 1/20 0.46
KAT2A Q92830 1/20 0.46
KAT2B Q92831 1/20 0.46
KAT5 Q92993 1/20 0.46
SAE1 Q9UBE0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10540759 0.94 POLB (0.51) POLBSLC16A3CYP1A2CYP2C19SMN1; SMN2
SCHEMBL11292670 0.88 ALDH1A1 (0.54) POLBLIPGSLC16A3THRATHRB
SCHEMBL10939734 0.88 ALDH1A1 (0.54) POLBLIPGSLC16A3THRATHRB
SCHEMBL2098312 0.88 THRA (0.49) PPARAPOLBLIPGSLC16A3THRA
SCHEMBL10910110 0.88 ALDH1A1 (0.54) POLBLIPGSLC16A3THRATHRB
SCHEMBL28954435 0.87 POLB (0.46) POLBCYP1A2CYP2C19SMN1; SMN2
SCHEMBL7471260 0.87 SLC16A3 (0.47) POLBSLC16A3THRATHRBCYP1A2
SCHEMBL15094109 0.86 POLB (0.60) PPARAPOLBLIPGSLC16A3SMN1; SMN2
SCHEMBL15093617 0.86 POLB (0.60) PPARAPOLBLIPGSLC16A3SMN1; SMN2
SCHEMBL29581002 0.86 POLB (0.60) PPARAPOLBLIPGSLC16A3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 PPARA 337/4885POLB 757/4885LIPG 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.